Evidence-based research has confirmed the role of gastrointestinal microbiota in regulating intestinal inflammation.These data have generated interest in developing microbiota-based therapies for the prevention and ma...Evidence-based research has confirmed the role of gastrointestinal microbiota in regulating intestinal inflammation.These data have generated interest in developing microbiota-based therapies for the prevention and management of inflammatory bowel disease(IBD).Despite in-depth understanding of the etiology of IBD,it currently lacks a cure and requires ongoing management.Accumulating data suggest that an aberrant gastrointestinal microbiome,often referred to as dysbiosis,is a significant environmental instigator of IBD.Novel microbiome-targeted interventions including prebiotics,probiotics,fecal microbiota transplant,and small molecule microbiome modulators are being evaluated as therapeutic interventions to attenuate intestinal inflammation by restoring a healthy microbiota composition and function.In this review,the effectiveness and challenges of microbiome-centered interventions that have the potential to alleviate intestinal inflammation and improve clinical outcomes of IBD are explored.展开更多
基金supported by Career Development Award[ID#597229]from Crohn’s and Colitis Foundation,National Institutes of Health(NIH)award R01 DK133334,and NIH T32 award T32DK120509.
文摘Evidence-based research has confirmed the role of gastrointestinal microbiota in regulating intestinal inflammation.These data have generated interest in developing microbiota-based therapies for the prevention and management of inflammatory bowel disease(IBD).Despite in-depth understanding of the etiology of IBD,it currently lacks a cure and requires ongoing management.Accumulating data suggest that an aberrant gastrointestinal microbiome,often referred to as dysbiosis,is a significant environmental instigator of IBD.Novel microbiome-targeted interventions including prebiotics,probiotics,fecal microbiota transplant,and small molecule microbiome modulators are being evaluated as therapeutic interventions to attenuate intestinal inflammation by restoring a healthy microbiota composition and function.In this review,the effectiveness and challenges of microbiome-centered interventions that have the potential to alleviate intestinal inflammation and improve clinical outcomes of IBD are explored.
